- Home
- PETZ vs ATHA Comparison
PETZ vs ATHA Comparison
Compare PETZ & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETZ
- ATHA
- Stock Information
- Founded
- PETZ 2002
- ATHA 2011
- Country
- PETZ China
- ATHA United States
- Employees
- PETZ N/A
- ATHA N/A
- Industry
- PETZ Steel/Iron Ore
- ATHA Medicinal Chemicals and Botanical Products
- Sector
- PETZ Industrials
- ATHA Health Care
- Exchange
- PETZ Nasdaq
- ATHA Nasdaq
- Market Cap
- PETZ 9.3M
- ATHA 10.6M
- IPO Year
- PETZ 2017
- ATHA 2020
- Fundamental
- Price
- PETZ $0.98
- ATHA $0.31
- Analyst Decision
- PETZ
- ATHA Buy
- Analyst Count
- PETZ 0
- ATHA 4
- Target Price
- PETZ N/A
- ATHA $11.25
- AVG Volume (30 Days)
- PETZ 11.1K
- ATHA 1.3M
- Earning Date
- PETZ 04-28-2025
- ATHA 07-31-2025
- Dividend Yield
- PETZ N/A
- ATHA N/A
- EPS Growth
- PETZ N/A
- ATHA N/A
- EPS
- PETZ 0.26
- ATHA N/A
- Revenue
- PETZ $563,726.00
- ATHA N/A
- Revenue This Year
- PETZ N/A
- ATHA N/A
- Revenue Next Year
- PETZ N/A
- ATHA N/A
- P/E Ratio
- PETZ $4.77
- ATHA N/A
- Revenue Growth
- PETZ 74664.72
- ATHA N/A
- 52 Week Low
- PETZ $0.65
- ATHA $0.22
- 52 Week High
- PETZ $1.74
- ATHA $3.67
- Technical
- Relative Strength Index (RSI)
- PETZ 44.43
- ATHA 49.52
- Support Level
- PETZ $0.90
- ATHA $0.29
- Resistance Level
- PETZ $1.05
- ATHA $0.35
- Average True Range (ATR)
- PETZ 0.07
- ATHA 0.03
- MACD
- PETZ -0.01
- ATHA -0.00
- Stochastic Oscillator
- PETZ 31.62
- ATHA 14.10
About PETZ TDH Holdings Inc.
TDH Holdings Inc is engaged in the business of manufacturing and selling pet food and restaurant operations. The company has two operating segments, which include Petfood sales and the Restaurant business. It has a focus on the Restaurant business segment and generates the majority of its revenue.
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.